Millipore Sigma Vibrant Logo

NA46 Anti-p300 Mouse mAb (NM-11)

Overview

Replacement Information

Key Specifications Table

Species ReactivityHostAntibody Type
H, RMMonoclonal Antibody

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
NA46-100UG
Retrieving availability...
Limited Availability
Limited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 100 μg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewRecognizes the p300 protein in A431, HeLa, and ML-1 cells.
      Catalogue NumberNA46
      Brand Family Calbiochem®
      References
      ReferencesDallas, P.B., et al. 1997. Hybridoma 16, 273.
      <→EMD:if(output-is PDS)→> Shisler, J., et al. 1996. J. Virol. 70, 68.
      Wang, H.G., et al. 1995. J. Virol. 69, 7917.
      Banerjee, A.C.,et al. 1994. Oncogene 9, 1733.
      Eckner, R., et al. 1994. Genes Dev. 8, 869.
      Abraham, S.E., et al. 1993. Oncogene 8, 1639.
      Wang, H.G., et al. 1993. J. Virol. 67, 476.
      Howe, J.A., and Bayley, S.T., 1992. Virology 186, 15.
      Rikitake, Y., and Moran, E., 1992. Mol. Cell. Biol. 11, 2826.
      Yaciuk, P., and Moran, W., 1991. Mol. Cell. Biol. 11, 5389.
      Egan, C., et al. 1988. Mol. Cell. Biol. 8, 3955.
      Yee, S. and Branton, P., 1985. Virology 147, 142. <→EMD:endif()→>
      Product Information
      FormLiquid
      FormulationIn 0.05 M sodium phosphate buffer, 50% glycerol.
      Positive controlA431, HeLa, or ML-1 cells
      PreservativeNone
      Quality LevelMQ100
      Applications
      Application ReferencesFrozen Sections Ogawa, H., et al. 2001. Brain Res. 890, 197. Immunoblotting Dallas, P.B., et al. 1997. Hybridoma 16, 273. Immunoprecipitation Abraham, S.E., et al. 1993. Oncogene 8, 1639.
      Key Applications Frozen Sections
      Immunoblotting (Western Blotting)
      Immunofluorescence
      Immunoprecipitation
      Paraffin Sections
      Application NotesFrozen Sections (see application references)
      Immunoblotting (1 µg/ml)
      Immunofluorescence (1-5 µg/ml)
      Immunoprecipitation (1 µg/sample)
      Paraffin Sections (1-5 µg/ml, heat pre-treatment required)
      Application CommentsAntibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenrecombinant, human p300 protein
      ImmunogenHuman
      Epitopewithin amino acids 2071-2091 near the CBP C-terminus
      CloneNM-11
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      • Rat
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage -20°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalog Number GTIN
      NA46-100UG 04055977227574

      Documentation

      Anti-p300 Mouse mAb (NM-11) SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-p300 Mouse mAb (NM-11) Certificates of Analysis

      TitleLot Number
      NA46

      References

      Reference overview
      Dallas, P.B., et al. 1997. Hybridoma 16, 273.
      <→EMD:if(output-is PDS)→> Shisler, J., et al. 1996. J. Virol. 70, 68.
      Wang, H.G., et al. 1995. J. Virol. 69, 7917.
      Banerjee, A.C.,et al. 1994. Oncogene 9, 1733.
      Eckner, R., et al. 1994. Genes Dev. 8, 869.
      Abraham, S.E., et al. 1993. Oncogene 8, 1639.
      Wang, H.G., et al. 1993. J. Virol. 67, 476.
      Howe, J.A., and Bayley, S.T., 1992. Virology 186, 15.
      Rikitake, Y., and Moran, E., 1992. Mol. Cell. Biol. 11, 2826.
      Yaciuk, P., and Moran, W., 1991. Mol. Cell. Biol. 11, 5389.
      Egan, C., et al. 1988. Mol. Cell. Biol. 8, 3955.
      Yee, S. and Branton, P., 1985. Virology 147, 142. <→EMD:endif()→>
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision05-September-2007 RFH
      ApplicationFrozen Sections (see application references)
      Immunoblotting (1 µg/ml)
      Immunofluorescence (1-5 µg/ml)
      Immunoprecipitation (1 µg/sample)
      Paraffin Sections (1-5 µg/ml, heat pre-treatment required)
      DescriptionPurified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with Sp2/0 mouse myeloma cells. Recognizes the p300 protein.
      Backgroundp300 is a nuclear phosphoprotein which was originally shown to specifically bind to adenovirus E1A protein. The binding of p300 to E1A occurs in the conserved region 1 (CR1) of E1A at a site which is close to but non-overlapping with that for the Rb family of proteins including p105 and p107. p300 has been shown to bind to the extreme N-terminal region requiring the presence of positively charged residues at positions 2 and 3 of E1A via a zinc-finger motif in the C-terminal portion of p300. While the binding of p300 and Rb to E1A is independent, it has been shown that upon binding, E1A mediates the physical contact between the two proteins. The p300 protein is actively phosphorylated in both quiescent and proliferating cells however the amount of phosphorylation increases during progression from late G1 into M phase of the cell cycle. In addition to the demonstrated binding of p300 to E1A it has also been shown to bind to other molecules including DNA (in a site specific manner) and to components of the TATA binding protein complexes (TBP). The TBP complex association is most likely with TFIID and occurs in a protein-protein dependent rather than a DNA dependent manner and, in such a complex, p300 functions as a co-activator of transcription.
      HostMouse
      Immunogen speciesHuman
      Immunogenrecombinant, human p300 protein
      Epitopewithin amino acids 2071-2091 near the CBP C-terminus
      CloneNM-11
      IsotypeIgG₁
      Specieshuman, not mouse, rat
      Positive controlA431, HeLa, or ML-1 cells
      FormLiquid
      FormulationIn 0.05 M sodium phosphate buffer, 50% glycerol.
      Concentration Label Please refer to vial label for lot-specific concentration
      PreservativeNone
      CommentsAntibody should be titrated for optimal results in individual systems.
      Storage Avoid freeze/thaw
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Toxicity Standard Handling
      ReferencesDallas, P.B., et al. 1997. Hybridoma 16, 273.
      <→EMD:if(output-is PDS)→> Shisler, J., et al. 1996. J. Virol. 70, 68.
      Wang, H.G., et al. 1995. J. Virol. 69, 7917.
      Banerjee, A.C.,et al. 1994. Oncogene 9, 1733.
      Eckner, R., et al. 1994. Genes Dev. 8, 869.
      Abraham, S.E., et al. 1993. Oncogene 8, 1639.
      Wang, H.G., et al. 1993. J. Virol. 67, 476.
      Howe, J.A., and Bayley, S.T., 1992. Virology 186, 15.
      Rikitake, Y., and Moran, E., 1992. Mol. Cell. Biol. 11, 2826.
      Yaciuk, P., and Moran, W., 1991. Mol. Cell. Biol. 11, 5389.
      Egan, C., et al. 1988. Mol. Cell. Biol. 8, 3955.
      Yee, S. and Branton, P., 1985. Virology 147, 142. <→EMD:endif()→>
      Application referencesFrozen Sections Ogawa, H., et al. 2001. Brain Res. 890, 197. Immunoblotting Dallas, P.B., et al. 1997. Hybridoma 16, 273. Immunoprecipitation Abraham, S.E., et al. 1993. Oncogene 8, 1639.